EVALUATION OF NO EVIDENCE OF PROGRESSION OR ACTIVE DISEASE (NEPAD) IN PATIENTS WITH PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS IN THE ORATORIO TRIAL

被引：0

作者：

Wolinsky, Jerry ^{[1
]}

Montalban, Xavier ^{[2
]}

Kappos, Ludwig ^{[3
]}

Hauser, Stephen ^{[4
]}

Giovannoni, Gavin ^{[5
]}

de Seze, Jerome ^{[6
]}

Bar-Or, Amit ^{[7
]}

Masterman, Donna ^{[8
]}

Bernasconi, Corrado ^{[9
]}

Wei, Wei ^{[9
]}

Garren, Hideki ^{[9
]}

Chin, Peter ^{[8
]}

Belachew, Shibeshih ^{[9
]}

Arnold, Doug L. ^{[10
,11
]}

机构：

[1] Univ Texas Hlth Sci Ctr Houston, McGovern Med Sch, Houston, TX 77030 USA

[2] Vall dHebron Univ Hosp, Barcelona, Spain

[3] Univ Hosp, Basel, Switzerland

[4] Univ Calif San Francisco, San Francisco, CA 94143 USA

[5] Queen Mary Univ London, London, England

[6] Univ Hosp Strasbourg, Strasbourg, France

[7] Univ Penn, Philadelphia, PA 19104 USA

[8] Genentech Inc, San Francisco, CA 94080 USA

[9] F Hoffmann La Roche Ltd, Basel, Switzerland

[10] McGill Univ, Montreal, PQ, Canada

[11] NeuroRx Res, Montreal, PQ, Canada

来源：

JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY | 2017年 / 88卷 / 05期

关键词：

D O I：

10.1136/jnnp-2017-316074.83

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

引用

页数：2

共 50 条

[11] Baseline Demographics and Disease Characteristics from ORATORIO, a Phase III Trial Evaluating Ocrelizumab in Patients with Primary Progressive Multiple Sclerosis
Montalban, X.
Hemmer, B.
Rammohan, K.
Giovannoni, G.
de Seze, J.
Bar-Or, A.
Arnold, D.
Sauter, A.
Leppert, D.
Chin, P.
Garren, H.
Messier, M.
Wolinski, J.
Kakarieka, A.
Masterman, D.
EUROPEAN JOURNAL OF NEUROLOGY, 2015, 22 : 706 - 706
[12] Prediction of Disease Progression in Primary Progressive Multiple Sclerosis
Patrucco, Liliana
Ignacio Rojas, Juan
Cristiano, Edgardo
NEUROLOGY, 2010, 74 (09) : A69 - A69
[13] An exploratory analysis of 12-and 24-week composite confirmed disability progression in patients with primary progressive multiple sclerosis in the ORATORIO trial
Giovannoni, G.
Arnold, D. L.
Bar-Or, A.
De Seze, J.
Hemmer, B.
Montalban, X.
Rammohan, K. W.
Belachew, S.
Bernasconi, C.
Chin, P.
Garren, H.
Masterman, D.
Sauter, A.
Wei, W.
Wolinsky, J.
MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 371 - 372
[14] Ocrelizumab reduces progression of upper extremity impairment in patients with primary progressive multiple sclerosis: Findings from the phase III randomized ORATORIO trial
Fox, Edward J.
Markowitz, Clyde
Applebee, Angela
Montalban, Xavier
Wolinsky, Jerry S.
Belachew, Sihbeshih
Fiore, Damian
Pei, Jinglan
Musch, Bruno
Giovannoni, Gavin
MULTIPLE SCLEROSIS JOURNAL, 2018, 24 (14) : 1862 - 1870
[15] Disability progression of active and nonactive primary and secondary progressive multiple sclerosis patients in the US
Watson, C.
Sadetsky, N.
Thirumalai, D.
Barlev, A.
Grant, N.
Jones, E.
Bogdanovich, S.
Kresa-Reahl, K.
EUROPEAN JOURNAL OF NEUROLOGY, 2022, 29 : 466 - 466
[16] Risk of requiring a wheelchair in primary progressive multiple sclerosis: Data from the ORATORIO trial and the MSBase registry
Butzkueven, Helmut
Spelman, Tim
Horakova, Dana
Hughes, Stella
Solaro, Claudio
Izquierdo, Guillermo
Kubala Havrdova, Eva
Grand'Maison, Francois
Prat, Alexandre
Girard, Marc
Hupperts, Raymond
Onofrj, Marco
Lugaresi, Alessandra
Taylor, Bruce
Giovannoni, Gavin
Kappos, Ludwig
Hauser, Stephen L.
Montalban, Xavier
Craveiro, Licinio
Freitas, Rita
Model, Fabian
Overell, James
Muros-Le Rouzic, Erwan
Sauter, Annette
Wang, Qing
Wormser, David
Wolinsky, Jerry S.
EUROPEAN JOURNAL OF NEUROLOGY, 2022, 29 (04) : 1082 - 1090
[17] Effect of ocrelizumab on upper limb function in patients with primary progressive multiple sclerosis in the ORATORIO study
Fox, E. J.
Markowitz, C.
Applebee, A.
Montalban, X.
Wolinsky, J. S.
Belachew, S.
Fiore, D.
Han, J.
Musch, B.
Giovannoni, G.
MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 658 - 659
[18] Phase III Study of Ocrelizumab in Patients with Primary Progressive Multiple Sclerosis: ORATORIO Study Design
Montalban, Xavier
Wolinsky, Jerry
Yin, Ming
Leppert, David
Glanzman, Robert
Chin, Peter
NEUROLOGY, 2011, 76 (09) : A319 - A320
[19] Disease activity impacts disability progression in primary progressive multiple sclerosis
Marrodan, M.
Bensi, C.
Pappolla, A.
Rojas, J. I.
Gaitan, M. I.
Ysrraelit, M. C.
Negrotto, L.
Fiol, M. P.
Patrucco, L.
Cristiano, E.
Farez, M. F.
Correale, J.
MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2020, 39
[20] Sustained reduction in confirmed disability progression in patients with primary progressive multiple sclerosis treated with ocrelizumab in the open-label extension period of the Phase III ORATORIO trial
Wolisnky, J. S.
Brochet, B.
Montalban, X.
Naismith, R. T.
Manfrini, M.
Garas, M.
Villoslada, P.
Model, F.
Hubeaux, S.
Kappos, L.
Hauser, S. L.
MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 490 - 491

← 1 2 3 4 5 →